Mw is synergistic with therapies that reduce disease burden (e.g. chemotherapy for infection or tumor) and therapies that reduce disease induced immune suppression (e.g. GITR agonist antibody or STAT3 inhibitor) (31, 34, 37, 38, 41, 44, 45). The gene discussed is STAT3; the disease is neoplasm.